Hot Products

Dammaradienyl acetate
Catalog No: CFN98874

Reference standards.

Dammarenediol II
Catalog No: CFN99476

Dammarenediol II may have the ability to prevent diabetic microvascular complications, including diabetic retinopathy, it can inhibit vascular endothelial growth factor (VEGF)-induced intracellular reactive oxygen species generation and stress fiber formation and vascular endothelial-cadherin disruption. The medicinally important dammarenediol II can be ectopically produced in tobacco, and the production of dammarenediol-II in tobacco plants allows them to adopt a viral defense system.

Damnacanthal
Catalog No: CFN98723

Damnacanthal possesses anti-cancer, immunomodulatory, antinociceptive and anti-inflammatory actions, it can treat or prevent hepatocellular carcinoma through its inhibitory effects on the HGF/c-Met axis. Damnacanthal inhibits mast cell activation induced by different stimuli and open a new window for the use of this compound as a mast cell stabilizer. Damnacanthal can inhibit the NF-κB/receptor-interacting protein-2/caspase-1 signal pathway by inhibiting p56lck tyrosine kinase.

Damulin A
Catalog No: CFN91838

Damulin A and Damulin B as potential activators of AMP-activated protein kinase (AMPK) from Gynostemma pentaphyllum, which may contribute to beneficial effect of G. pentaphyllum on glucose and lipid metabolism.

Damulin B
Catalog No: CFN91837

Damulin A and Damulin B as potential activators of AMP-activated protein kinase (AMPK) from Gynostemma pentaphyllum, which may contribute to beneficial effect of G. pentaphyllum on glucose and lipid metabolism.

Danshenol A
Catalog No: CFN92167

Danshenol A has strong aldose reductase (AR) inhibitory activity, has IC50 of 0.10 microM which is comparable to that of epalrestat in clinical use. Danshenol A also has antitumor activity in T-24, QGY, K562, Me180 and BIU87 cell lines, shows inhibited growth of K562 (IC50 = 0.53 μg/mL), T-24 (IC50 = 7.94 μg/mL), QGY (IC50 = 4.65 μg/mL) and Me180 (IC50 = 6.89 μg/mL) cell lines.

Danshenol B
Catalog No: CFN90474

Danshenol B has aldose reductase(AR) inhibitory activity.

Danshensu
Catalog No: CFN99539

Danshensu has anxiolytic-like, cardioprotective, neuroprotective, and antioxidant activities. It can enhance HO-1 expression to suppress 6-OHDA-induced oxidative damage via PI3K/Akt/Nrf2 signaling pathways and can reduce 6-OHDA-induced dopaminergic neuronal loss in zebrafish. Chronic treatment with danshensu can prevent/attenuate the formation of atherosclerosis.

Danshenxinkun A
Catalog No: CFN90325

Danshenxinkun A, Danshenxinkun B and Neocryptotanshinone may intervene thrombotic diseases by adjusting the targets mainly involved in pathways of endocrine system, signal transduction, signaling molecules and interaction, cell motility, environmental adaptation and nervous system. Oleoyl danshenxinkun A also selectively inhibits rabbit platelet aggregation induced by arachidonic acid.

Danshenxinkun B
Catalog No: CFN90326

Danshenxinkun B has antioxIdant activity, it may have the potential of being used as natural antioxidants in foods and cosmetics.